Tab Application Banner
  • Users Online: 923
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
BRIEF REPORT
Year : 2019  |  Volume : 14  |  Issue : 2  |  Page : 136-142

Meeting report: MyoIN – Pan-India collaborative network for myositis research


1 Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
2 Department of Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
3 Department of Clinical Immunology and Rheumatology, St John's Hospital, Bengaluru, Karnataka, India
4 Consultant Rheumatologist, Mumbai, Maharashtra, India

Date of Web Publication8-Jul-2019

Correspondence Address:
Dr. Latika Gupta
Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow - 226 014, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/injr.injr_40_19

Rights and Permissions
  Abstract 


Rheumatology in India, albeit old, has lagged behind in research on epidemiology and outcomes of chronic rheumatic diseases. The realization about paucity of Indian data has created the felt need for cohort-building and sustainable research. With this comes the dawn of collaborative research. Myositis is one such rare disease with considerable morbidity and mortality, where little is known about the behavior of the disease and treatment practices in the Indian setting. In recent years with the availability of myositis-specific autoantibodies, newer clinic-serologic associations have been described. Collaborative efforts in rare diseases from the Western world have yielded exemplary results. Hence, a pan-India collaborative network called MyoIN (Myositis India Collaborative Effort) was formed to collect data on patients with inflammatory myositis in a standardized format including clinical and investigational parameters both at presentation and follow up to build up a large series prospectively. This report describes the activities since the inception of this group.

Keywords: Collaborative efforts, India, myositis


How to cite this article:
Gupta L, Appani SK, Janardana R, Muhammed H, Lawrence A, Amin S, Shobha V, Rajasekhar L, Misra R. Meeting report: MyoIN – Pan-India collaborative network for myositis research. Indian J Rheumatol 2019;14:136-42

How to cite this URL:
Gupta L, Appani SK, Janardana R, Muhammed H, Lawrence A, Amin S, Shobha V, Rajasekhar L, Misra R. Meeting report: MyoIN – Pan-India collaborative network for myositis research. Indian J Rheumatol [serial online] 2019 [cited 2022 May 17];14:136-42. Available from: https://www.indianjrheumatol.com/text.asp?2019/14/2/136/262350




  Report Top


There is a paucity of data on epidemiology, clinical and serological profile, treatment practices, and outcome of Indian myositis patients. Myositis being a heterogeneous disease with a complex interplay of genetic and environment factors varies in presentation and behavior across countries. Socioeconomic and cultural aspects also emerge as major players in decision-making in the clinic when it comes to the management of this challenging disease in this part of the world. Knowledge on clinical profile, behavior of the disease, and prescription trends in Indian patients can go a long way to streamline and improvise management, as well as shape up future research. There was thus a felt need for the establishment of a Pan-India collaborative network for collecting data on this rare disease. The conduct of the Indian National Conference of Rheumatology (IRACON) under the banner of the Indian Rheumatology Association (IRA) brought alongside the opportunity to embark on such an initiative. The IRACON 2016 in Kochi saw the presence of stalwarts in myositis research from overseas, Professor Ingrid Lundberg and Dr. Kenneboyina Nagaraju.[1] Amidst talks by them, the first Myositis Special Interest Group (SIG) was held at Kochi. The planning for such a collaborative effort was underway then, which took better shape at the next IRACON 2017 held at Sanjay Gandhi Postgraduate Institute, Lucknow.[2] Rheumatologists catering to adults and children were invited to be the part of SIG in myositis through IRA. The primary aim was to develop a consensus protocol for data collection across the country, ensuring uniformity in content and clarity of methods.

The second meeting, held in Lucknow, attracted 49 attendees which included academicians and private practitioners of adult and childhood rheumatology alike from across the country and few from outside the country. The meeting was presided by Dr. Liza Rajasekhar, and the new scoring and classification criteria were discussed. Five case summaries were precirculated for scoring using the new ACR/EULAR Classification Criteria. These cases included one comparator case of metabolic myopathy. Differences in scoring were discussed in an effort to achieve consistency. Issues with variability in scoring were discussed. Based on the above deliberation, it was decided to form a common case record form (CRF) and collate baseline data across centers. Meeting also featured a short video presentation of manual muscle testing-8 scoring. A discussion followed video presentation so that uniformity in grading and scoring could be achieved.

The merits of good research lie in uniformity in the scoring of outcome measures. The International Myositis Assessment and Clinical Studies Group (IMACS) 1 committee has been instrumental in devising such methods in the past. Moreover, this very aspect was tested before embarking on the initiative by mailing cases as Google forms to a set of practicing rheumatologists interested in the disease. This was done with the objectives of exploring common knowledge about outcome measures in inflammatory myositis. The lack of such uniformity and the need to bring in the same was brought out by this exercise, which was later dwelt on by Dr. Latika Gupta in the discussion on the scope of various IMACS outcome measures. A discussion regarding points of contention in classification scoring and IMACS outcome measures followed. Myositis pro forma currently used by various centers were also discussed and ideas for the development of a common CRF was exchanged. This was followed by a 10 min talk by Dr. Varaprasad on the development of a consensus treatment protocol for IIM in India. Members of the meeting then discussed on potential additional participants to SIG and were decided to invite them.

It was decided to invite academic and practice centers to be part of the same. Six centers across the country have opted for participation into the same. Professor Ramnath Misra was chosen as the chairperson for 2 years by consensus. The name MyoIN was decided for collaboration. The MyoIN consortium was established with the prime intent of developing a registry of Indian patients with inflammatory myositis. Data on prevalent treatment practices and outcomes would be captured. Identification of poor prognostic markers could be useful for better management of cases. The ground would also be set for sample collection and characterizing genotype and biomarker research.

A CRF was formulated. Outcome measures were included in the CRF. The first CRF was rolled out on December 31, 2017, and tested on 25 cases at each center. A Skype meeting was done to resolve the first round of queries. Following this, the form underwent more than 10 rounds of correction. The overlap form was designed on January 8, 2018. Subsequently, follow-up data sheet was formulated. A separate form was devised for patient with juvenile dermatomyositis (JDM) to factor in inclusions from the JDM optimal data set [https://www.researchgate.net/publication/333918126_Meeting_Report_MyoIN_-_Pan-India_collaborative_network_for_myositis_research]. A consensus on the changes suggested was reached on February 15, 2018, and the CRF locked and circulated for use. A glossary explaining the various items in the CRF was devised for the comfort of the unaware user. Efforts for ethics clearance for collaborative effort and database structure were initiated.

As of December 2018, six centers have started collating data with ethical committee clearance. As part of MyoIN collaborative effort, two abstracts were presented at IRACON 2018.[3] Efforts for biobanking sera have been initiated, with SGPGI as the apex laboratory for processing of these sera. Dr. Rajasekhar has been instrumental in devising a database for collecting information on the registry, which has primarily been put to use in compilation of data.


  Conclusion Top


A Pan-India collaborative network called MyoIN was formulated with six centers across the country for uniformity in methods of clinical research. This is one of the first steps in successful collaboration through SIG across academician and practitioners of rheumatology in India. Uniformity in data collection methods hope to provide a model for sustainable clinical research.

Collaborative efforts with other international groups should help in filling the research gaps in this area.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.





 
  References Top

1.
Available from: http://www.iracon2016.com. [Last accessed on 2019 Jun 24].  Back to cited text no. 1
    
2.
Available from: http://www.iracon.in/2017/sceintific_programe.php. [Last accessed on 2019 Jun 24].  Back to cited text no. 2
    
3.
Available from: https://www.indianjrheumatol.com/temp/IndianJRheumatol13693-1426114_035741.pdf. [Last accessed on 2019 Jun 24].  Back to cited text no. 3
    



This article has been cited by
1 Peripheral T helper subset profiling in idiopathic inflammatory myositis: Proof of concept
Anamika Kumari Anuja, Pankti Mehta, Mantabya Kumar Singh, Harshit Singh, Alok Nath, Zia Hashim, Ajmal Khan, Mansi Gupta, Durga P. Misra, Vikas Agarwal, Latika Gupta
Reumatología Clínica. 2022;
[Pubmed] | [DOI]
2 The prevalence and clinical characteristics of anti-HMGCR (anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) antibodies in idiopathic inflammatory myopathy: an analysis from the MyoCite registry
Latika Gupta, Arvind Nune, R. Naveen, Ritu Verma, Pallavi Prasad, Rajat Kharbanda, Upendra Rathore, Mohit Kumar Rai, Mantabya Kumar Singh, Anamika Kumari Anuja, Vikas Agarwal
Rheumatology International. 2022;
[Pubmed] | [DOI]
3 Prevalent Drug Usage Practices in Adults and Children With Idiopathic Inflammatory Myopathies
Pankti Mehta, Upendra Rathore, R. Naveen, Rudrarpan Chatterjee, Vikas Agarwal, Rohit Aggarwal, Latika Gupta
JCR: Journal of Clinical Rheumatology. 2022; 28(2): 89
[Pubmed] | [DOI]
4 Anti-mitochondrial antibodies in Indian patients with idiopathic inflammatory myopathies
Prithvi Sanjeevkumar Gaur, Naveen R, Anamika Kumari Anuja, Mantabya Kumar Singh, Mohit Kumar Rai, Rizwan Muhammed, Ankit Kumar Sahu, Vikas Agarwal, Latika Gupta
International Journal of Rheumatic Diseases. 2022;
[Pubmed] | [DOI]
5 Validation of two simple patient-centered outcome measures for virtual monitoring of patients with idiopathic inflammatory myositis
R. Naveen, Darpan R. Thakare, Vikas Agarwal, Rohit Aggarwal, Latika Gupta
Clinical Rheumatology. 2021;
[Pubmed] | [DOI]
6 Myositis mimics
Sujata Ganguly, Rudrarpan Chatterjee, Abhishek Zanwar, Latika Gupta
Indian Journal of Rheumatology. 2021; 16(4): 427
[Pubmed] | [DOI]
7 High serum myostatin level suggests accelerated muscle senescence in active idiopathic inflammatory myositis
AnamikaKumari Anuja,Danveer Bhadu,R Naveen,MantabyaKumar Singh,MohitKumar Rai,Vikas Agarwal,Latika Gupta
Indian Journal of Rheumatology. 2021; 0(0): 0
[Pubmed] | [DOI]
8 Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis
Latika Gupta,R Naveen,Priyanka Gaur,Vikas Agarwal,Rohit Aggarwal
Seminars in Arthritis and Rheumatism. 2021; 51(1): 113
[Pubmed] | [DOI]
9 Clinical profile and treatment outcomes in antisynthetase syndrome: a tertiary centre experience
Sreejitha Kodakkattil Sreevilasan, Phanikumar Devarasetti, Narendra Kumar Narahari, Anitha Desai, Liza Rajasekhar
Rheumatology Advances in Practice. 2021; 5(Supplement): ii10
[Pubmed] | [DOI]
10 High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care centre in northern India
Pankti Mehta,Vikas Agarwal,Latika Gupta
Rheumatology. 2021;
[Pubmed] | [DOI]
11 High burden of infections in Indian patients with Idiopathic Inflammatory Myopathy: validation of observations from the MyoCite dataset
Rudrarpan Chatterjee,Pankti Mehta,Vikas Agarwal,Latika Gupta
Rheumatology. 2021;
[Pubmed] | [DOI]
12 NMR-based serum and muscle metabolomics for diagnosis and activity assessment in idiopathic inflammatory myopathies
Anupam Guleria,Umesh Kumar,Dinesh Kumar,Naveen R,Anamika Kumari Anuja,Mantabya Kumar Singh,Pulak Sharma,Vikas Agarwal,Ramnath Misra,Latika Gupta
Analytical Science Advances. 2021;
[Pubmed] | [DOI]
13 Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort
R. Naveen,Upendra Rathore,Vikas Agarwal,Latika Gupta
Rheumatology International. 2021;
[Pubmed] | [DOI]
14 Poor maternal and foetal outcomes in women with systemic sclerosis: an interview-based study at a tertiary centre
Rajat Kharbanda,R. Naveen,Durga Prasanna Misra,Latika Gupta,Vikas Agarwal
Rheumatology International. 2021;
[Pubmed] | [DOI]
15 Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study
Sai Kumar Dunga,Chengappa Kavadichanda,Latika Gupta,R. Naveen,Vikas Agarwal,Vir Singh Negi
Rheumatology International. 2021;
[Pubmed] | [DOI]
16 Insights into the knowledge, attitude and practices for the treatment of idiopathic inflammatory myopathy from a cross-sectional cohort survey of physicians
Latika Gupta,Hafis Muhammed,R. Naveen,Rajat Kharbanda,Harikrishnan Gangadharan,Durga P. Misra,James B. Lilleker,Hector Chinoy,Vikas Agarwal
Rheumatology International. 2020;
[Pubmed] | [DOI]
17 Teleconsultation experience with the idiopathic inflammatory myopathies: a prospective observational cohort study during the COVID-19 pandemic
R. Naveen,T. G. Sundaram,Vikas Agarwal,Latika Gupta
Rheumatology International. 2020;
[Pubmed] | [DOI]
18 Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy
Latika Gupta,Hector Chinoy
Current Opinion in Rheumatology. 2020; 32(6): 553
[Pubmed] | [DOI]
19 Reporting Survey Based Studies – a Primer for Authors
Prithvi Sanjeevkumar Gaur,Olena Zimba,Vikas Agarwal,Latika Gupta
Journal of Korean Medical Science. 2020; 35(45)
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Report
Conclusion
References

 Article Access Statistics
    Viewed2388    
    Printed53    
    Emailed0    
    PDF Downloaded189    
    Comments [Add]    
    Cited by others 19    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]